Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J Combines Ortho Biotech, Centocor

This article was originally published in The Pink Sheet Daily

Executive Summary

At least 400 jobs lost to fallout from anemia-drug troubles.

You may also be interested in...

J&J’s R&D Spending To Ease As Firm Focuses On Taking Pipeline To Market

Firm reports slight sales growth as generics and a constricting ESA market take their toll on current products.

Centocor: Ustekinumab Works in Psoriasis After One Year

Second Phase III pivotal study backs fewer-dose benefit

J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications

Johnson & Johnson’s Centocor unit is positioning the next generation anti-TNF as a once-monthly treatment.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts